Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
| العنوان: | Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1) |
|---|---|
| المؤلفون: | Ulrike Pötschger, Hans Loibner, Holger N. Lode, Shifra Ash, Godfrey Chi-Fung Chan, Penelope Brock, Alberto Garaventa, Dominique Valteau-Couanet, Victoria Castel, Ruth Ladenstein, Andrew D.J. Pearson, Guenter Schreier, Jean Michon, Toby Trahair, Ellen Ruud, Genevieve Laureys, Peter F. Ambros, Maja Beck-Popovic, Henrik Schroeder, Roberto Luksch, Cormac Owens, Maria Rita Castellani, Keith Holmes, Mark N. Gaze |
| المصدر: | Cancers, Vol 12, Iss 2, p 309 (2020) Cancers Volume 12 Issue 2 Ladenstein, R, Pötschgerulrike.poetschger@ccri.at, U, Valteau-couanet, D, Luksch, R, Castel, V, Ash, S, Laureys, G, Brock, P, Michon, J M, Owenscormac.owens@olchc.ie, C, Trahair, T, Chan, G C F, Ruud, E, Schroeder, H, Beck-popovic, M, Schreier, G, Loibner, H, Ambros, P, Holmes, K, Castellani, M R, Gaze, M N, Garaventa, A, Pearson, A D J & Lode, H N 2020, ' Investigation of the role of dinutuximab beta-based immunotherapy in the siopen high-risk neuroblastoma 1 trial (HR-NBL1) ', Cancers, vol. 12, no. 2, 309 . https://doi.org/10.3390/cancers12020309 r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
| بيانات النشر: | MDPI AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, dinutuximab beta, Cancer Research, medicine.medical_specialty, Autologous Stem Cell Rescue, medicine.medical_treatment, lcsh:RC254-282, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Neuroblastoma, medicine, Stage (cooking), Isotretinoin, high-risk neuroblastoma, High-risk neuroblastoma, business.industry, Dinutuximab beta, Immunotherapy, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Confidence interval, Radiation therapy, 030104 developmental biology, 030220 oncology & carcinogenesis, Cohort, dinutuximab beta, high-risk neuroblastoma, immunotherapy, immunotherapy, business, medicine.drug |
| الوصف: | To explore the effects of immunotherapy in the International Society of Paediatric Oncology Europe Neuroblastoma Group SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1 trial), two cohorts were studied: one prior to and one after the introduction of dinutuximab beta. All patients received standard induction and high-dose therapy (HDT) with autologous stem cell rescue (ASCR) the local control comprised surgery and radiotherapy to the primary tumour site, followed by isotretinoin. A landmark timepoint of 109 days, resulting from the median time between ASCR and initiation of immunotherapy, was used to define patients&rsquo eligibility in the pre-immunotherapy analysis cohort. Median follow-up was 5.8 years (inter-quartile range (IQR): 4.2&ndash 8.2 years) for 844 eligible patients balanced for risk factors, such as age, sex, stage 4, MYCN amplification and response prior to HDT. The five-year event-free and overall survival (95% confidence interval (CI) of 466 patients not receiving immunotherapy was 42% (38&ndash 47%) and 50% (46&ndash 55%) but was 57% (51&ndash 62%) and 64% (59&ndash 69%) for 378 patients receiving immunotherapy (p < 0.001). A multivariate analysis identified absence of immunotherapy (p = 0.0002, hazard ratio (HR) 1.573) type of HDT (p = 0.0029, HR 1.431) less than complete response prior to maintenance therapy (p = 0.0043, HR 1.494) and > 1 metastatic compartment at diagnosis (p < 0.001, HR 2.665) as risk factors for relapse or progression. Results suggest an important role for dinutuximab beta-based immunotherapy within the treatment concepts applied in HR-NBL1/SIOPEN. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2072-6694 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c473380705672f3226abb700809e06d2 https://www.mdpi.com/2072-6694/12/2/309 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....c473380705672f3226abb700809e06d2 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726694 |
|---|